NPY and postural orthostatic tachycardia syndrome: LL‐TS represents a promising adjunctive therapy for individuals with POTS following post‐acute COVID‐19 infection, offering a noninvasive approach for reductions in upright heart rate response, alterations in HRV, and decreases in NPY levels.